ArticleDiagnostic microbiology and infectious disease2021
Diagnostic pre-screening method based on N-gene dropout or delay to increase feasibility of SARS-CoV-2 VOC B.1.1.7 detection.
Article in Diagnostic microbiology and infectious disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Assessment of the Effective Sensitivity of SARS-CoV-2 Sample Pooling Based on a Large-Scale Screening Experience: Retrospective Analysis.JMIR public health and surveillance · 2024Article
- Partial N-gene target failure in the Seegene Allplex SARS-CoV-2 Master Assay as a proxy of SARS-CoV-2 BA.2.86.Microbiology spectrum · 2024Article
- SARS-CoV-2 viral variants can rapidly be identified for clinical decision making and population surveillance using a high-throughput digital droplet PCR assay.Scientific reports · 2023Article
- Impact of G29179T mutation on two commercial PCR assays for SARS-CoV-2 detection.Journal of virological methods · 2023Article
- A high-resolution melt curve toolkit to identify lineage-defining SARS-CoV-2 mutations.Scientific reports · 2023Article
- Long-term validation of a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for the rapid detection of SARS-CoV-2 from March 2020 to October 2021 in Central Africa, Gabon.PLoS neglected tropical diseases · 2022Article
- A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants.Microbiology spectrum · 2022Article
- Rapid Detection of the Omicron (B.1.1.529) SARS-CoV-2 Variant Using a COVID-19 Diagnostic PCR Assay.Microbiology spectrum · 2022Article
- RT-PCR/MALDI-TOF Diagnostic Target Performance Reflects Circulating SARS-CoV-2 Variant Diversity in New York City.The Journal of molecular diagnostics : JMD · 2022Article
- Emergence of a mutation in the nucleocapsid gene of SARS-CoV-2 interferes with PCR detection in Canada.Scientific reports · 2022Article
- A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants.medRxiv : the preprint server for health sciences · 2022Article
- Unusual N Gene Dropout and Ct Value Shift in Commercial Multiplex PCR Assays Caused by Mutated SARS-CoV-2 Strain.Diagnostics (Basel, Switzerland) · 2022Article
- Comparative Evaluation of Six SARS-CoV-2 Real-Time RT-PCR Diagnostic Approaches Shows Substantial Genomic Variant-Dependent Intra- and Inter-Test Variability, Poor Interchangeability of Cycle Threshold and Complementary Turn-Around Times.Pathogens (Basel, Switzerland) · 2022Article
- Use of the Ct difference between the Nucleocapside (N) and the Spike (S) or RNA-dependent RNA polymerase (RdRP) genes as a preliminary screening for SARS-CoV-2 variants with the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay: Searching the N in Variants.Journal of virological methods · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To compare the RT-PCR Allplex SARS-CoV-2/FluA/FluB/RSV Assay (Allplex assay) with other methods of detection of VOC B.1.1.7. Suspected and non-suspected cases of VOC B.1.1.7 were defined according to the VirSNiP assay, which detects N501Y and deletion H69-V70. For pre-screening, the Allplex™ and TaqPath assays were used. One hundred and sixteen suspected and 113 non-suspected cases were included. In the suspected cases, the Allplex assay showed N-gene dropout, or delayed Ct values of 6.27 ± 1.21 and 6.66 ± 1.41 compared with those of the RdRP and S-gene target, respectively. Agreement between the Allplex and TaqPath assays was 100% when the RdRP and S-gene targets had Ct values <35. Agreement between the Allplex and VirSNiP assays was 100% with Ct value <30. The Allplex assay showed excellent agreement with the current pre-screening method for VOC B.1.1.7. In addition, its automated processing enhances the feasibility of widespread use in laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.